Celcuity Inc. entered into an Amended and Restated Loan and Security Agreement with Innovatus Life Sciences Lending Fund I, LP, and Oxford Finance LLC, for term loans of up to $180 million, to be used for working capital purposes and to fund the Phase 3 VIKTORIA-2 clinical trial.